ZYUS Life Sciences (TSXV:ZYUS) ROE %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZYUS ZYUS Life Sciences Corp TSXV:ZYUS
16 GF Score
Price C$0.50
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences ROE %?

ZYUS Life Sciences TSXV:ZYUS 16 ROE % is 0.00% as of Mar. 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 937 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 106723.48% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ZYUS Life Sciences's annualized net income for the quarter that ended in Mar. 2026 was C$-12.25 Mil. ZYUS Life Sciences's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was C$-22.54 Mil. Therefore, ZYUS Life Sciences's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for ZYUS Life Sciences's ROE % or its related term are showing as below:

TSXV:ZYUS's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.06
* Ranked among companies with meaningful ROE % only.

ZYUS Life Sciences  (TSXV:ZYUS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-12.248/-22.5355
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.248 / 0.488)*(0.488 / 4.874)*(4.874 / -22.5355)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2509.84 %*0.1001*N/A
=ROA %*Equity Multiplier
=-251.23 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-12.248/-22.5355
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-12.248 / -12.248) * (-12.248 / -9.18) * (-9.18 / 0.488) * (0.488 / 4.874) * (4.874 / -22.5355)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.3342 * -1881.15 % * 0.1001 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


ZYUS Life Sciences ROE % Related Terms


ZYUS Life Sciences ROE % Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences ROE % Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
0.00 -520.08 -305.81 -380.47 0.00

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSXV:ZYUS vs ZTS, UTHR: ROE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences ROE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's ROE % falls into.


TSXV:ZYUS
16GF Score
ZYUS Life Sciences Corp TSXV:ZYUS
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences ROE % Calculation

ZYUS Life Sciences's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-21.731/( (-5.344+-21.12)/ 2 )
=-21.731/-13.232
=N/A %

ZYUS Life Sciences's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-12.248/( (-21.12+-23.951)/ 2 )
=-12.248/-22.5355
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
ZYUS Life Sciences (TSXV:ZYUS) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #999999 out of 937 companies in the Drug Manufacturers industry.
Is ZYUS Life Sciences' ROE % too high?
ZYUS Life Sciences' current ROE % is 0.00%. Based on the distribution chart, ZYUS Life Sciences ranks #999999 out of 937 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #999999 out of 937 companies for ROE %. This places ZYUS Life Sciences in the lower half of its industry. The industry median ROE % is 6.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.06, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current ROE % of 0.00%. The current ROE % is 0.00%. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZLSCF:USA
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score

Get the complete analysis for TSXV:ZYUS

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price